Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel Sells 25,105 Shares

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 25,105 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $202,346.30. Following the transaction, the chief executive officer now owns 343,576 shares of the company’s stock, valued at approximately $2,769,222.56. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Replimune Group Trading Down 4.7%

NASDAQ:REPL opened at $8.35 on Friday. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The stock has a market cap of $643.08 million, a price-to-earnings ratio of -2.72 and a beta of 0.68. The business has a fifty day moving average of $8.63 and a 200-day moving average of $11.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the company earned ($0.25) earnings per share. Equities analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. HC Wainwright upped their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. upped their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $19.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of REPL. Boxer Capital Management LLC bought a new position in shares of Replimune Group in the fourth quarter worth $21,754,000. Tang Capital Management LLC lifted its holdings in shares of Replimune Group by 125.0% in the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock valued at $32,697,000 after buying an additional 1,500,000 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after buying an additional 1,083,633 shares during the period. MPM Bioimpact LLC acquired a new stake in shares of Replimune Group in the fourth quarter valued at $11,504,000. Finally, RTW Investments LP lifted its holdings in shares of Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company’s stock valued at $25,007,000 after buying an additional 931,223 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.